98%
921
2 minutes
20
Frailty is a frequent condition among kidney transplant candidates (KTc) that confers poor outcomes after transplantation. We aimed to establish frailty prevalence in a representative sample of KTc in Spain. We conducted a multicenter cross-sectional study including 1194 KTc ≥50 years. Frailty was assessed by the FRAIL scale. Mean age was 64.2 years; 38.4% were female. Median Charlson comorbidity index (CCI) was 6 [4-7] and the total number of medications was 9 [7-12]. We found that 8.2% of patients were frail and 41.5% were pre-frail. Frailty was more frequent among females (60.2% of frail vs. 32.8% of robust; p < 0.001), hemodialysis patients (74.5% of frail vs. 67.1% of robust; p = 0.02), and those with a high burden of disease (54.6% of frail patients with CCI >6 vs. 29.3% of robust; p < 0.001). The multivariable analysis confirmed that frailty was associated with the female sex (OR 3.9 [2.5-6.2]); higher CCI (>6 OR 2.9 [1.6-54]); and the number of medications (OR -per medication- 1.13 [1.07-1.2]). Almost 50% of KTc in Spain are pre-frail or frail. Frailty is more prevalent between women and patients with high comorbidity burden. Identifying those candidates at risk is essential to establish risks and implement strategies to minimize them.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236369 | PMC |
http://dx.doi.org/10.3389/ti.2025.14098 | DOI Listing |
Front Biosci (Landmark Ed)
August 2025
Department of Physiology, HeartOtago, School of Biomedical Sciences, University of Otago, 9010 Dunedin, New Zealand.
Sarcopenia is the progressive loss of skeletal muscle mass, strength, and function, significantly contributing to frailty, disability, and mortality in aging populations. As life expectancy rises, sarcopenia presents a growing public health challenge, increasing healthcare costs, and diminishing quality of life. Despite its prevalence, sarcopenia is often underdiagnosed due to limitations in current diagnostic tools, including the lack of standardized cut-off values and reliance on physical performance tests.
View Article and Find Full Text PDFNutr J
September 2025
Department of Geriatric, The First Hospital of China Medical University, No. 155 Nanjing North Street, Heping Ward, Shenyang, 110001, China.
Objective: This study analyzed data from the US population to examine how oral microbiome diversity and diet quality individually and synergistically affect frailty.
Methods: This study included 6,283 participants aged 20 years or older from the 2009-2010 and 2011-2012 NHANES cycles. A frailty index (FI) consisting of 36 items was developed, with items related to nutritional status excluded.
Ann Hematol
September 2025
Centre on Aging and Mobility, University of Zurich, Zurich, Switzerland.
While frailty and anemia are prevalent conditions in aging linked to adverse outcomes, their relationship remains understudied in generally healthy older adults. We conducted a post-hoc observational study among all participants of DO-HEALTH, the largest European clinical trial designed to support healthy aging. Our analysis examined whether baseline hemoglobin levels and anemia are associated with being at least pre-frail at baseline and any yearly follow-up time point over three years.
View Article and Find Full Text PDFClin Neurol Neurosurg
September 2025
Department of Internal Medicine, Baylor Scott and White Health, Temple, TX, USA.
Background: Carotid artery stenosis prevalence increases with age, and carotid endarterectomy (CEA) is a possible treatment option. However, nonagenarians are at high risk of experiencing postoperative complications and are often not considered surgical candidates. We aimed to identify risk factors associated with postoperative myocardial infarction (MI), stroke, and death within 30 days for nonagenarians undergoing CEA and to analyze the predictive ability of modified frailty indices (mFI) in predicting adverse outcomes for this population.
View Article and Find Full Text PDFJ Frailty Aging
September 2025
Department of Geriatric Medicine, Klinikum Fürth, Fürth, Germany; Institute for Biomedicine of Ageing, Friedrich-Alexander-University, Erlangen-Nürnberg, Germany.
Purpose: Sarcopenia and sarcopenic obesity are defined by the loss of muscle strength and mass. Both diseases pose a growing global challenge. Their prevalences vary between studied populations.
View Article and Find Full Text PDF